IRVINE, Calif.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced the launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio. This new pulse sequence marks the next evolution of the VARIPULSE Platform and is designed to improve procedural efficiencyi,ii while reinforcing its established […]
Tag: Johnson and Johnson
Johnson and Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch
LIMA, Peru–(BUSINESS WIRE)–Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atrial fibrillation. This incorporation represents a significant advance in the approach to cardiac arrhythmias, with benefits in terms of safety, precision, and procedural efficiency.1 “With this launch, Peru joins the Latin American countries that already have this world-class innovation, used in international referenc
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
MADRID, Aug. 31, 2025 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when…
Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress
VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE™ Platform in nearly 800 enrolled patientsi IRVINE, Calif., Sept. 2, 2025 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) — Johnson & Johnson MedTech, a global leader in…
Johnson & Johnson Receives FDA Approval for Updated VARIPULSE™ Platform Irrigation Rate
New flow rate guidance designed to optimize irrigation and support consistent procedural outcomes 10,000+ VARIPULSE global procedures with low adverse event rate reinforces platform’s strong safety profile New Brunswick, NJ – July 14, 2025 – Today, Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced U.S. Food and Drug […]
Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting
Omny-IRE data demonstrated the investigational OMNYPULSE™ Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durability at three months, with promising safety outcomes1 Additional data presented from VARIPURE registry2 and Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter3 pre-clinical study underscore safety and real-world efficiency across Johnson & Johnson MedTech’s expanding pulsed field ablation […]
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs Includes four planned new manufacturing facilities, with ground-breaking today in North Carolina on $2 billion+ facility Total Company U.S. economic impact estimated to be more than $100 billion per year NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Today, Johnson […]
Johnson & Johnson Statement on VARIPULSE™ U.S. External Evaluation
New Brunswick, NJ, January 8, 2025 – At Johnson & Johnson MedTech, the health and safety of our patients is our top priority. On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four […]



